Fig 1: Validation analysis of differentially regulated proteins (peptides) in cerebrospinal fluid of psychiatric disorders.Shown are median with an interquartile range of the ratios of light peptides to spiked synthetic heavy peptides in the different patient cohorts (number of patients in brackets). Asterisks refer to statistically significant differences with Kruskal–Wallis test and Dunn’s Multiple comparison test, **p < 0.01, *p < 0.05. CON controls, MDD major depressive disorder, BI bipolar disorder, SCZ schizophrenia, VGF neurosecretory protein VGF, LINGO1 leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 1, GRIA4 glutamate ionotropic receptor AMPA type subunit 4, CNTNAP4 contactin-associated protein-like 4, SERPINI1 neuroserpin, PCSK1N proprotein convertase subtilisin/kexin type 1 inhibitor, CARTPT cocaine- and amphetamine-regulated transcript protein, NPTXR neuronal pentraxin receptor, CNDP1 carnosine dipeptidase 1, NXPH1 neurexophilin 1, CBLN4 cerebellin-4, NRXN3 neurexin 3.